Glaukos (NYSE:GKOS) vs. Monogram Orthopaedics (NASDAQ:MGRM) Financial Comparison

Monogram Orthopaedics (NASDAQ:MGRM) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Monogram Orthopaedics and Glaukos, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monogram Orthopaedics	0	0	1	1	3.50
Glaukos	1	0	11	1	2.92

Monogram Orthopaedics presently has a consensus price target of $5.40, suggesting a potential upside of 88.81%. Glaukos has a consensus price target of $156.17, suggesting a potential upside of 64.04%. Given Monogram Orthopaedics’ stronger consensus rating and higher probable upside, research analysts clearly believe Monogram Orthopaedics is more favorable than Glaukos.

Profitability

This table compares Monogram Orthopaedics and Glaukos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monogram Orthopaedics	N/A	-130.90%	-106.38%
Glaukos	-39.04%	-16.53%	-10.61%

Earnings & Valuation

This table compares Monogram Orthopaedics and Glaukos”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monogram Orthopaedics	$364,999.00	276.51	-$13.74 million	($0.46)	-6.22
Glaukos	$383.48 million	14.04	-$134.66 million	($2.87)	-33.17

Monogram Orthopaedics has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Monogram Orthopaedics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.4% of Monogram Orthopaedics shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 28.1% of Monogram Orthopaedics shares are held by company insiders. Comparatively, 6.4% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Monogram Orthopaedics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Summary

Monogram Orthopaedics beats Glaukos on 8 of the 14 factors compared between the two stocks.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.